Plain-English translation of NCT04804241 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a medication called can help slow the progression of memory loss and thinking problems in people in the early stages of Alzheimer's disease or mild cognitive impairment. Researchers will follow participants for one year while some take the medication daily and others take a placebo (a pill with no active ingredient). The study will measure changes in memory, thinking abilities, daily functioning, and brain health using cognitive tests, blood work, spinal fluid samples, and brain imaging.
Currently, there are very few treatments that can slow down memory loss in the early stages of Alzheimer's disease. This trial is exploring whether this medication might work as a disease-modifying treatment — meaning it could potentially slow or stop the progression of cognitive decline before more serious symptoms develop.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic multiple times over 78 weeks total. For the first year (52 weeks), you would take either the study medication or a placebo pill once daily at home. You'll have in-person visits at the start, at 26 weeks, at 52 weeks, and again at 78 weeks (6 months after stopping the medication). At these visits, you'll have cognitive tests, blood pressure checks, blood work, an EKG heart recording, and either a spinal fluid collection or a brain PET scan. You'll also participate in brain wave recording tests. Safety check-in visits will happen at weeks 4, 12, and 36.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States